biostudies-literatureZeng XNIA NIH HHSNational Institutes of HealthNIH HHS40https://www.ebi.ac.uk/biostudies/studies/S-EPMC11095038biostudies-literatureUnknown19(1)Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD tMolecular neurodegenerationAlzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.PMC11095038P30 AG066468R01 AG083874Klunk WECohen ADLee JZeng XTudorascu DLVillemagne VLLopez OIZetterberg HBerman SBIkonomovic MDKamboh MISehrawat APascoal TASnitz BEChen YKofler JSweet RAPfister ALafferty TKKarikari TKBlennow KfalseAlzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD t2024-01-01T00:00:00Z2024 May2026-07-16T07:33:54.813Z2026-07-09T10:44:04.255ZS-EPMC110950383875057010.1186/s13024-024-00711-1